A biotech developing oral pills for rare hormone diseases, like acromegaly, aiming to replace daily injections with a once-a-day tablet. Think of it as turning a painful shot into a simple pill.
No meaningful revenue yet—2025 brought in just USD 0.01B, while net losses hit USD 0.47B. Money comes only from partnerships or grants, not product sales, so it's pre-commercial with no recurring income.
Its oral non-peptide agonists are novel, but big pharma like Novartis and Ipsen dominate acromegaly with injectables, and Pfizer has oral candidates. The moat is weak because clinical-stage drugs face high failure risk and no approved product to lock in custom
Buy (sector percentile 85) — value D, growth A, profitability D, momentum A, revisions C+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Deal announced with ~$10.0B total equity value, ~$8.8B net of estimated cash acquired
Quarterly loss narrower than Zacks consensus, revenue topped estimates
None yet
None yet
Crinetics Pharmaceuticals (CRNX) is highlighted as a stock reaching a 52-week high, appearing on lists alongside energy and other healthcare companies, indicating positive momentum.
Main discussion
All these stocks hit new 52 WEEK HIGHS at some point today Energy Transfer $ET Permian Resources $PR Merck $MRK Charles Schwab $SCHW ONEOK $OKE Cenovus Energy $CVE Roivant Sciences $ROIV Crinetics Pharmaceuticals $CRNX Ovintiv $OVV Everpure $P SM Energy $SM Targa Resources $TRGP
This is what the new 52W high list looks like by theme: - Healthcare - Pharma - Energy - Midstream - Refiners - Defensives $MRK $AMGN $ARGX $HALO $CRNX $PTGX $LH $THC $ET $OKE $TRGP $PSX $MPC $VLO $DINO $PBF $OVV $PR Meanwhile, growth/AI land continues to struggle for sustained l
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
